Identify pediatric central nervous system cancers

Pediatric central nervous system (CNS) tumors have higher instances of gene fusions than adults. And some pediatric tumor types, including medulloblastoma, have molecular characteristics affiliated with distinct clinical outcomes.1 Precision analysis that simultaneously detects for multiple biomarkers can provide a heightened understanding of the genetic landscape of a child’s tumor.

Pediatric neuro-oncology test menu


Our pediatric-focused molecular testing provides robust coverage of established and emerging cancer-related gene expression, including mutations, rearrangements, fusions, and copy number variants. Developed in collaboration with Mayo Clinic neuro-oncologists, molecular geneticists, and genetic counselors, our testing covers an array of CNS cancers, including medulloblastoma, pilocytic astrocytoma, pediatric-type gliomas, and neuroblastoma.

Key testing


  1. Menyhárt O, Győrffy B. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches. Cancer Metastasis Rev. 2020;39(1):211-233. doi:10.1007/s10555-020-09854-1.
  2. Rare cancers of childhood treatment (PDQ®) – Health Professional Version. National Cancer Institute. Updated Dec. 8, 2022. Accessed March 6, 2023.
  3. Lee J, Gillam L, Visvanathan K, Hansford J, McCarthy M. Clinical utility of precision medicine in pediatric oncology: a systemic review. JCO Precision Oncology. 2021 :5, 1088-1102
  4. Goldman R, Chang S, Cochrane D. Improving diagnosis of pediatric central nervous system tumors: aiming for early detection. CMAJ. March 27, 2017 189 (12) E459-E463; doi:

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.